Following a positive opinion of Almirall’s new LAMA as a maintenance bronchodilator by the Committee for Medicinal Products for Human Use of the European Medicines Agency (CHMP) on 28 May 2012, the European Commission finally approved the medicine on 24 July 2012.
Almirall general manager Carlos Gallardo said, "Our long-term alignment with Quintiles will help us to ensure that new therapeutic options are made available for COPD patients throughout the UK."
Quintiles UK commercial solutions managing director Robert Taylor said the partnership allows the company’s engaged workforce to drive success across the life cycle of Almirall’s respiratory products.
"The FDA also issued final positive feedback on Almirall’s first product in COPD on July 24," Taylor added.